Soligenix Inc - Warrants (07/12/2021)
SNGXW
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.94M
Close$
$3.70
40964.4% upside
Current Fair Value
40964.4% upsideUndervalued by 40964.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.94 Million |
|---|---|
| Enterprise Value | $-3,564,058.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.14 |
| Beta | 1.61 |
| Outstanding Shares | 15,951,949 |
Return
| Return on Equity | -84.99% |
|---|---|
| Return on Assets | -53.80% |
| Return on Invested Capital | -157.51% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | 0.32 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.33 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Soligenix Inc
18 employees
CEO: Christopher Schaber Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.